|
Affiliation |
Hospital Department of Pharmacy |
Graduating School 【 display / non-display 】
-
-2006.03
Kumamoto University Faculty of Pharmaceutical Science Graduated
Graduate School 【 display / non-display 】
-
-2014.03
Kyushu University Graduate School, Division of Pharmaceutical Sciences Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2017.12-Now
Akita University Hospital Department of Pharmacy Lecturer
Research Achievements 【 display / non-display 】
-
Hayato Yokota, Yumiko Akamine, Mizuki Kobayashi, Takuro Kitabayashi, Misato Horie, Tentaro Endo, Takechiyo Yamada, Masafumi Kikuchi
Journal of pharmaceutical health care and sciences ( Journal of Pharmaceutical Health Care and Sciences ) 10 ( 1 ) 2024.08
Research paper (journal)
BACKGROUND: Naldemedine is an orally available peripherally acting μ-opioid receptor antagonist approved to treat opioid-induced constipation (OIC). It is contraindicated for patients with known or suspected gastrointestinal obstruction to protect against naldemedine-induced perforation. Here, we report a clinical case of suspected perforation of a diverticulum in the sigmoid colon associated with naldemedine. CASE PRESENTATION: The patient was a 65-year-old man with a history of oral cancer who had been prescribed oxycodone (20 mg/day) for cancer pain. On day 0, the patient started naldemedine 0.2 mg once daily before bedtime for OIC. The dose of oxycodone was increased for pain control up to 60 mg/day. On day 35 of naldemedine treatment, the patient developed fever and abdominal pain, and his frequency of defecation had decreased. Initial laboratory results showed a C-reactive protein (CRP) level of 28.5 mg/dL and white blood cell (WBC) count of 13,500/µL. On day 37, the patient still had tenderness in his lower abdomen. Abdominal computed tomography revealed free air in the abdominal cavity suggesting an intestinal perforation. A Hartmann procedure was performed. Histopathological findings showed numerous diverticula in the sigmoid colon, some of which were perforated. CONCLUSIONS: These results suggest that the effects of OIC may have compressed the intestinal tract, which was followed by naldemedine-activation of peristalsis, which led to the onset of intestinal perforation. In patients with pre-existing diverticular disease, we should monitor for increased WBC counts and CRP levels after the initiation of treatment with naldemedine, and consider performing appropriate tests early in the event of abdominal complaints.
-
Kazuma Fujita, Yumiko Akamine, Haruka Igarashi, Yayoi Fukushi, Katsuya Sasaki, Koji Fukuda, Masafumi Kikuchi, Hiroyuki Shibata
Japanese journal of clinical oncology ( Japanese Journal of Clinical Oncology ) 54 ( 11 ) 1165 - 1170 2024.06
Research paper (journal)
BACKGROUND: The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin. METHODS: The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death. RESULTS: The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin. CONCLUSION: Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.
-
Hayato Yokota, Ruriko Asahi, Yumiko Akamine, Mizuki Kobayashi, Hiyu Wakabayashi, Sho Sakamoto, Yuji Okuda, Kazuhiro Sato, Katsutoshi Nakayama, Masafumi Kikuchi
Journal of pharmaceutical health care and sciences ( Journal of Pharmaceutical Health Care and Sciences ) 10 ( 1 ) 2024.06
Research paper (journal)
BACKGROUND: Anamorelin, a drug to treat cancer cachexia, binds to ghrelin receptors and improves body weight and appetite. In clinical trials in Japan, patients experienced a 10.7% frequency of stimulant conduction system depression as a severe side effect. Although rare, anamorelin sometimes causes fatal arrhythmias. Because patients with cancer cachexia are often underweight, data on the safety of anamorelin in obese patients are lacking. We report a case of QT interval prolongation after anamorelin administration to an obese patient with non-small cell lung cancer. CASE PRESENTATION: A female patient with a body mass index of 30 kg/m2 underwent immunotherapy for lung adenocarcinoma. She presented with severe weight loss, anorexia, and fatigue. She had no history of heart disease. On day 12, after administration of anamorelin 100 mg once daily, the patient developed nausea, diarrhea, and anorexia, which were considered cancer immunotherapy-induced immune-related adverse events, and she was admitted to the hospital. An electrocardiogram (ECG) on admission showed a QTc interval of 502 ms. On admission, her hepatic function was Child-Pugh class B, and anamorelin was discontinued the next day. On day 3 after anamorelin discontinuation, the QTc interval was prolonged by up to 557 ms, then decreased to 490 ms on day 6, and improved to 450 ms on day 16. Re-administration of anamorelin was avoided. CONCLUSIONS: When administering anamorelin to obese patients, we should be aware of the potential for stimulatory conduction system depression, as in underweight patients. Therefore, we should monitor patients by ECG from the early stages of anamorelin administration. Anamorelin is lipophilic, and its volume of distribution is increased in obese patients. Consequently, obese patients may continue to have QT interval prolongation after discontinuation of anamorelin, requiring long-term side-effect monitoring.
-
Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo
YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan ) 143 ( 4 ) 377 - 383 2023
Research paper (journal)
-
Fukushi Yayoi, Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo
YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan ) 143 ( 11 ) 963 - 969 2023
Research paper (journal)
-
An update on the clinical pharmacokinetics of fexofenadine enantiomers.
Akamine Y and Miura M.
Expert Opinion on Drug Metabolism & Toxicology ( Taylor and Francis Group ) 2018.04
Introduction and explanation (scientific journal) Domestic Co-author
-
Determination of Plasma Concentrations of Imatinib by a Novel Automated Analyzer Based on High-Performance Liquid Chromatography
福司弥生, 赤嶺由美子, 松下美由紀, 森川悟, 三浦昌朋, 三浦昌朋
YAKUGAKU ZASSHI (Web) 143 ( 11 ) 2023
-
Questions related to quantification of the blood concentrations of psychotropics.
赤嶺由美子
臨床精神薬理 25 ( 1 ) 83 - 88 2022.01
-
Personalized therapy of Psychotropic Drugs based on Pharmacokinetics-Related Biomarkers
赤嶺由美子
日本臨床精神神経薬理学会プログラム・抄録集 31st 2021
-
Comparison electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients.
Akamine Y, Sato S, Kagaya H, Ohkubo T, Satoh S, Miura M
Journal of Clinical Pharmacy and Therapeutics 2018.04
-
OATPS-INHIBITED EFFECTS OF RIFAMPICIN ON THE PHARMACOKINETICS OF FEXOFENADINE ENANTIOMERS
Akamine Yumiko, Miura Masatomo, Yasui-Furukori Norio, Uno Tsukasa
Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics ( The Japanese Society for the Study of Xenobiotics ) 25 ( 0 ) 158 - 158 2010
◆Original paper【 display / non-display 】
◆Introduction and explanation【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2021.04 - 2025.03
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2021.04 - 2025.03
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2021.04 - 2025.03
-
Grant-in-Aid for Early-Career Scientists
Project Year： 2018.04 - 2021.03 Investigator(s): Akamine Yumiko
-
Grant-in-Aid for Early-Career Scientists
Project Year： 2018.04 - 2021.03 Investigator(s): Akamine Yumiko